This meeting took place in the past. For a complete list of the meetings for the upcoming/current season, see our meeting list or click on related meetings tab below to check for related meeting(s).
Web Desc
New Therapeutics for Diabetes and Obesity
Organizer(s): Richard D. DiMarchi, Matthias H. Tschöp and Nancy A. Thornberry
Date: April 17 - 20, 2016
Location: Estancia La Jolla Hotel & Spa, La Jolla, CA, USA
Sponsored by Arena Pharmaceuticals, Inc., Janssen R&D: Pharmaceutical Companies of Johnson & Johnson, Merck & Co., Inc., Novo Nordisk A/S and Regeneron Pharmaceuticals, Inc.
Summary of Meeting:
Type 2 diabetes (T2DM) is a global pandemic with approximately 350 million patients worldwide, driven largely by increasing prevalence of obesity. Multiple options exist for treatment of the primary disease and the array of associated cardiovascular disorders. Nonetheless, the majority of patients do not reach recommended glycemic goals, and there is an urgent need for more efficacious, cost-effective and safe therapies. The regulatory hurdle for new drugs is sizable and challenged by the specific requirement for cardiovascular mortality study. Given the magnitude of the challenges, highly collaborative efforts involving academia, biotech, pharma, regulatory agencies, patient advocacy groups and other key stakeholders are required to identify and advance new therapies that are substantially differentiated from current disease management. The major goals of this meeting are to: 1) Define the distance between current therapy relative to what is most needed to address successfully the near-term challenges of the disease and the wave of later-stage disease-specific complications; 2) Communicate the most important scientific advances in metabolic diseases with the intimate details that often escape peer-review publication and are seminal to drug R&D; and 3) Create opportunities for candid discussion among key stakeholders (academia, biotech, industry, regulatory, venture community, etc.) to identify new business processes, along with new science to streamline the successful conversion of ideas to medicines. Is it anticipated that the perspectives and science presented at this meeting, together with multiple platforms for discussion and interaction, will facilitate the identification of collaborations and opportunities for the discovery of transformative treatment of diabetes and related disorders. The meeting will be uniquely led by experienced drug-hunters with world-class academic credentials to help foster the translation of basic science to breakthrough therapeutics. We anticipate that this meeting will be of interest to a broad and diverse group of individuals interested in drug discovery and cost-effective development with an emphasis on quality, speed and value.
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Arena Pharmaceuticals, Inc.Janssen Research and Development, LLCMerck & Co., Inc.Novo Nordisk A/SRegeneron Pharmaceuticals, Inc.
We gratefully acknowledge additional support for this conference from:
Journal of Lipid ResearchEducational grant from LillyMercodia, Inc.Profil® Institute for Clinical Research, Inc.Translational Research Institute for Metabolism and Diabetes
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Novo Nordisk A/S

Novo Nordisk Pharmaceuticals, Inc.
We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Grant No. 5R13DK104616-01

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Grant No. 5R13DK104616-02
The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found